-
Advancing precision oncology with metabolomics and machine learning
A new study led by Dr. Rafael Nambo Venegas and colleagues, published in Metabolomics (Feb 2025), presents a high-accuracy predictive model for forecasting response to neoadjuvant therapy in breast cancer…
-
Risk-based breast cancer screening: A shift toward personalized prevention
In a recent study published in December 2024, Professor Isabel Rubio and her colleagues critically examined the limitations of current age-based breast cancer screening programs, which remain standard in most…
-
Temocillin in the Spotlight: Dr. Francesco Cogliati Dezza on Tackling Antimicrobial Resistance
At ESCMID Global 2025, Infectious Disease Frontier interviewed Dr. Francesco Cogliati Dezza to explore the renewed clinical relevance of temocillin. With resistance to broad-spectrum antibiotics on the rise, temocillin is…
-
Professor Li Zhang’s Team Publishes Again in Nature Medicine
This marks the second time in just one month that Professor Zhang’s team has been featured in Nature Medicine. Their previous publication, released on March 13, presented the results of…
-
Mok Talk | Lung Cancer Leadership, Innovation, and the Power of Collaboration
In this special episode of Mok Talk, Professor Tony Mok (The Chinese University of Hong Kong) sits down with three rising oncology experts Professor Yang Xia (Zhejiang University), Professor Wenhua…
-
Temocillin in the Spotlight: Dr. Francesco Cogliati Dezza on Tackling Antimicrobial Resistance
At ESCMID Global 2025, Infectious Disease Frontier sat down with Dr. Francesco Cogliati Dezza to discuss the renewed clinical relevance of temocillin. As resistance to broad-spectrum antibiotics continues to rise,…
-
Advancing the Diagnosis and Prevention of Congenital CMV: Insights from Dr. Marianne Leruez-Ville
Dr. Marianne Leruez-Ville, a prominent clinical virologist, shared her insights into improving diagnostic tools, the promise of vaccines and antivirals, and how a multidisciplinary approach is key to optimizing outcomes…
-
Temocillin and the Search for Carbapenem Alternatives: A Conversation with Dr. Francesco Cogliati Dezza at ESCMID Global 2025
IDF: The issue of carbapenem resistance is becoming increasingly severe, while drugs like Temocillin seem to be overlooked. What do you think is the significance of seeking carbapenem alternative solutions?…
Connecting Medical Expertise through Media